Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Human tumor growth suppression by apoptosis induced with anti-ErbB-2 chimeric monoclonal antibody.

Literature DB >> 9685861

Human tumor growth suppression by apoptosis induced with anti-ErbB-2 chimeric monoclonal antibody.

S Sasaki¹, M Tsujisaki, T Jinnohara, T Ishida, M Sekiya, M Adachi, S Takahashi, Y Hinoda, K Imai.

Abstract

We established an anti-ErbB-2 mouse-human chimeric monoclonal antibody (MoAb), CH401, which was able to kill cancer cells overexpressing the ErbB-2 protein in vitro. The analysis of the killing mechanism indicated that MoAb CH401 might be the first anti-erbB-2 mouse-human chimeric MoAb which can induce the apoptosis of cancer cells, since morphological changes and DNA fragmentation were recognized in MoAb CH401-treated cells. The ErbB-2 receptor appears to have two opposing functions: acting as a receptor both for a growth factor and for an apoptotic factor. Our results indicate that MoAb CH401 treatment may prove to be very useful for cancer therapy.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 1998 PMID： 9685861 PMCID： PMC5921853 DOI： 10.1111/j.1349-7006.1998.tb03298.x

Source DB: PubMed Journal: Jpn J Cancer Res ISSN： 0910-5050

26 in total

Review 1. Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy.

Authors: E S Vitetta; J W Uhr
Journal: Cancer Res Date: 1994-10-15 Impact factor: 12.701

2. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors: D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal: Science Date: 1989-05-12 Impact factor: 47.728

3. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.

Authors: R M Hudziak; G D Lewis; M Winget; B M Fendly; H M Shepard; A Ullrich
Journal: Mol Cell Biol Date: 1989-03 Impact factor: 4.272

4. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies.

Authors: J A Drebin; V C Link; D F Stern; R A Weinberg; M I Greene
Journal: Cell Date: 1985-07 Impact factor: 41.582

5. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies.

Authors: G D Lewis; I Figari; B Fendly; W L Wong; P Carter; C Gorman; H M Shepard
Journal: Cancer Immunol Immunother Date: 1993-09 Impact factor: 6.968

6. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification.

Authors: D J Venter; N L Tuzi; S Kumar; W J Gullick
Journal: Lancet Date: 1987-07-11 Impact factor: 79.321

Human tumor growth suppression by apoptosis induced with anti-ErbB-2 chimeric monoclonal antibody.

Review 1. Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy.

2. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

3. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.

4. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies.

5. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies.

6. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification.

7. Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells.

8. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo.

9. A human/mouse chimeric monoclonal antibody against intercellular adhesion molecule-1 for tumor radioimmunoimaging.

10. Establishment and characterization of mouse-human chimeric monoclonal antibody to erbB-2 product.

1. Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine.

2. Enhanced anti-tumor effect of trastuzumab in combination with cisplatin.